-
Posted: March 28th, 2024, 2:00am GMT
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Drug: HAIC-GEMOX+Cadonilimab+Regorafenib
Sponsors: Fudan University
Recruiting
-
Posted: March 22nd, 2024, 2:00am GMT
Conditions: Primary Liver Cancer
Sponsors: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Recruiting
-
Posted: March 22nd, 2024, 2:00am GMT
Conditions: Pharmacological Action
Interventions: Dietary Supplement: Virgin Coconut Oil
Sponsors: Food and Nutrition Research Institute, Philippines; Ateneo de Manila University; De La Salle Medical and Health Sciences Institute
Active, not recruiting
-
Posted: March 21st, 2024, 2:00am GMT
Conditions: Pancreaticoduodenectomy
Interventions: Procedure: Main pancreatic duct and biliary duct external drainage; Procedure: Main pancreatic duct and biliary duct internal drainage
Sponsors: Shanghai Zhongshan Hospital; Huadong Hospital; RenJi Hospital; The First People's Hospital of Yunnan; First Affiliated Hospital Xi'an Jiaotong University; The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Not yet recruiting
-
Posted: March 15th, 2024, 2:00am GMT
Conditions: Intrahepatic Cholangiocarcinoma; Chemotherapy Effect
Interventions: Drug: Floxuridine; Procedure: Selective Internal Radiation Therapy (SIRT)
Sponsors: Oslo University Hospital
Recruiting
-
Posted: March 15th, 2024, 2:00am GMT
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Surufatinib、Toripalimab、Gemcitabine、Oxaliplatin
Sponsors: Fudan University
Not yet recruiting
-
Posted: March 12th, 2024, 2:00am GMT
Conditions: Hepatocellular Carcinoma; Cholangiocarcinoma; Liver Metastases
Interventions: Procedure: Laparoscopic ablation; Procedure: Open ablation
Sponsors: Rigshospitalet, Denmark
Recruiting
-
Posted: March 12th, 2024, 2:00am GMT
Conditions: Advanced Solid Tumor; Unresectable Solid Tumor; Metastatic Solid Tumor; Cholangiocarcinoma
Interventions: Drug: Afatinib; Drug: Pemigatinib
Sponsors: Massachusetts General Hospital; Boehringer Ingelheim; Incyte Corporation
Not yet recruiting
-
Posted: March 8th, 2024, 3:00am GMT
Conditions: Duodenal Adenoma; Complication of Treatment
Interventions: Procedure: Stent Placement in Pancreatic and Bile Ducts
Sponsors: Beijing Friendship Hospital
Completed
-
Posted: March 7th, 2024, 3:00am GMT
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Drug: combined therapy using gemcitabine and cisplatin chemotherapy, Lenvatinib and Adebrelimab
Sponsors: Nanfang Hospital, Southern Medical University
Recruiting
-
Posted: March 6th, 2024, 3:00am GMT
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Procedure: HAIC; Drug: Adebrelimab; Drug: Apatinib
Sponsors: Lei ZHAO
Not yet recruiting
-
Posted: March 4th, 2024, 3:00am GMT
Conditions: Intrahepatic Cholangiocarcinoma; Machine Learning
Interventions: Procedure: lymph nodes dissection
Sponsors: West China Hospital
Recruiting
-
Posted: March 4th, 2024, 3:00am GMT
Conditions: Metastatic Colorectal Cancer; Pancreas Adenocarcinoma; Cholangiocarcinoma
Interventions: Diagnostic Test: Multiplex PCR-test for circulating tumor DNA
Sponsors: Oslo University Hospital
Recruiting
-
Posted: February 29th, 2024, 3:00am GMT
Conditions: Primary Sclerosing Cholangitis; Inflammatory Bowel Diseases
Interventions: Biological: Faecal Microbiota Transplant; Other: FMT Placebo
Sponsors: University of Birmingham; PSC Support; Life Arc
Not yet recruiting
-
Posted: February 28th, 2024, 3:00am GMT
Conditions: Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence
Interventions: Drug: Adebrelimab, Apatinib, Gemcitabine, cisplatin
Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not yet recruiting
-
Posted: February 28th, 2024, 3:00am GMT
Conditions: Solid Tumors (Pancreatic Cancer, Esophageal Cancer, Gastric Cancer, Cholangiocarcinoma, Lung Cancer and Ovarian Cancer)
Interventions: Drug: Allogeneic NK(CCT-ANK-11)
Sponsors: Escure Biotechnology Corp; Beijing Kejing Biotechnology Corp.
Recruiting
-
Posted: February 28th, 2024, 3:00am GMT
Conditions: Biliary Tract Cancer; HER2 Gene Mutation
Interventions: Drug: Zanidatamab; Drug: Cisplatin; Drug: Gemcitabine; Drug: Pembrolizumab; Drug: Durvalumab
Sponsors: Jazz Pharmaceuticals
Recruiting
-
Posted: February 26th, 2024, 3:00am GMT
Conditions: Biliary Stricture; Bile Duct Cancer; Pancreas Cancer
Sponsors: Peking University Third Hospital; Beijing Tsinghua Changgeng Hospital
Not yet recruiting
-
Posted: February 23rd, 2024, 3:00am GMT
Conditions: Bile Duct Cancer
Interventions: Drug: Gemcitabin, Cisplatin and Durvalumab; Procedure: Biliary Radiofrequency Ablation; Procedure: Endoscopic Retrograde Cholangio-Pancreatography with stenting
Sponsors: Insel Gruppe AG, University Hospital Bern; Swiss Cancer League
Not yet recruiting
-
Fetched: February 21st, 2024, 5:01am GMT
Conditions: Biliary Tract Cancer; Cholangiocarcinoma; Gallbladder Cancer; Intrahepatic Cholangiocarcinoma; Perihilar Cholangiocarcinoma; Extrahepatic Cholangiocarcinoma; Hilar Cholangiocarcinoma; Distal Bile Duct Cancer
Interventions: Diagnostic Test: Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring
Sponsors: University of Washington; Natera, Inc.; SEngine Precision Medicine, Inc.
Recruiting
-
Posted: February 15th, 2024, 3:00am GMT
Conditions: Hepatocellular Carcinoma; Cholangiocarcinoma; Hepatobiliary Cancer
Interventions: Behavioral: Target Navigation Pilot Program
Sponsors: University of Miami; The V Foundation
Not yet recruiting
-
Posted: February 14th, 2024, 3:00am GMT
Conditions: Pancreatic Cancer; Cholangiocarcinoma; Ampullary Cancer; Biliary Stricture; Gallstone Disease
Interventions: Diagnostic Test: Small RNA Sequencing and Validation of candidate miRNAs
Sponsors: Imperial College London; Royal Surrey County Hospital NHS Foundation Trust; Royal Free Hospital NHS Foundation Trust
Completed
-
Posted: February 13th, 2024, 3:00am GMT
Conditions: Malignant Mesothelioma; Colorectal Cancer; Bile Duct Cancer; Rectal Cancer; Ovary Cancer; Pancreatic Cancer; Breast Cancer Female
Interventions: Biological: UCMYM802 Injection
Sponsors: UTC Therapeutics Inc.; Peking University Cancer Hospital & Institute
Recruiting
-
Posted: February 8th, 2024, 3:00am GMT
Conditions: Neoplasms, Bile Duct
Interventions: Device: 1.1mm flexible Cryoprobe SU
Sponsors: Erbe Elektromedizin GmbH
Recruiting
-
Posted: February 2nd, 2024, 3:00am GMT
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Drug: HAIC+TAE; Drug: Tislelizumab; Drug: Surufatinib
Sponsors: Qilu Hospital of Shandong University; BeiGene
Recruiting
-
Posted: February 2nd, 2024, 3:00am GMT
Conditions: Solid Tumor
Interventions: Drug: ZG005 Powder for Injection; Drug: Donafenib Tosilate Tablets
Sponsors: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Not yet recruiting
-
Posted: January 25th, 2024, 3:00am GMT
Conditions: Biliary Tract Cancer; Portal Vein Embolization
Interventions: Procedure: Potal vein embilization
Sponsors: Seoul National University Hospital
Completed
-
Posted: January 25th, 2024, 3:00am GMT
Conditions: Gallstone; Gallbladder Cancer; Bile Duct Injury
Sponsors: University of Edinburgh; University of Birmingham
Recruiting
-
Posted: January 22nd, 2024, 3:00am GMT
Conditions: Ampullary Adenoma
Interventions: Procedure: Endoscopic papillectomy
Sponsors: Asian Institute of Gastroenterology, India
Not yet recruiting
-
Posted: January 17th, 2024, 3:00am GMT
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Adebrelimab; Drug: Lenvatinib; Drug: Gemcitabine; Drug: Oxaliplatin
Sponsors: The First Affiliated Hospital with Nanjing Medical University; Jiangsu Hengrui Pharmaceutical Co., Ltd.
Recruiting
-
Posted: January 10th, 2024, 3:00am GMT
Conditions: Pancreatic Adenocarcinoma; Cholangiocarcinoma; Lung Cancer; Stomach Cancer; Esophageal Carcinoma; Breast Cancer
Interventions: Drug: Paclitaxel Polymeric Micelles for Injection
Sponsors: Liu Huang
Recruiting
-
Posted: January 9th, 2024, 3:00am GMT
Conditions: Jaundice, Obstructive; Cholangiopancreatography, Endoscopic Retrograde; Endoscopic Ultrasound-Guided Drainage
Interventions: Procedure: EUS-BD; Procedure: ERCP-BD
Sponsors: Peking Union Medical College Hospital
Not yet recruiting
-
Posted: January 9th, 2024, 3:00am GMT
Conditions: Pancreatic Cancer; Advanced Biliary Cancer
Interventions: Drug: anti-EX02 CAR T cells
Sponsors: Zhang Xiaofeng,MD; Zeno Therapeutics Pte. Ltd
Not yet recruiting
-
Posted: January 8th, 2024, 3:00am GMT
Conditions: Cholangiocarcinoma Non-resectable
Interventions: Procedure: drug eluting beads-transcatheter arterial chemoembolization; Drug: envatinib plus anti-PD(L)1
Sponsors: Ze-yang Ding, MD; Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer (CCGLC)
Recruiting
-
Posted: January 5th, 2024, 3:00am GMT
Conditions: Cholangiocarcinoma Non-resectable
Interventions: Procedure: HAIC; Drug: Lenvatinib plus pucotenlimab
Sponsors: Ze-yang Ding, MD; Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer (CCGLC)
Recruiting
-
Posted: January 5th, 2024, 3:00am GMT
Conditions: Cholangiocarcinoma Non-resectable
Interventions: Procedure: DEB-TACE; Drug: Lenvatinib plus pucotenlimab
Sponsors: Tongji Hospital; Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer (CCGLC)
Recruiting
-
Posted: December 21st, 2023, 3:00am GMT
Conditions: Biliary Tract Cancer; HER2 Gene Mutation
Interventions: Drug: SOC plus trastuzumab and pembrolizumab
Sponsors: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest; Medizinische Hochschule Hannover, Germany, Prof. Dr. Arndt Vogel; MSD Sharp & Dohme GmbH, Germany
Not yet recruiting
-
Posted: December 21st, 2023, 3:00am GMT
Conditions: Locally Advanced Cholangiocarcinoma; Metastatic Cholangiocarcinoma; Recurrent Cholangiocarcinoma; Stage III Hilar Cholangiocarcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Hilar Cholangiocarcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Biological: Sacituzumab Govitecan
Sponsors: University of Kansas Medical Center; National Cancer Institute (NCI)
Recruiting
-
Posted: December 19th, 2023, 3:00am GMT
Conditions: Cholangiocarcinoma; Klatskin Tumor; Bile Duct Cancer; Liver Cancer
Interventions: Procedure: Intraductal biliary radiofrequency ablation
Sponsors: Universitätsklinikum Hamburg-Eppendorf
Not yet recruiting
-
Posted: December 13th, 2023, 3:00am GMT
Conditions: Biliary Tract Carcinoma; Radiotherapy; Radio-frequency Ablation
Interventions: Procedure: ID-RFA and Radiotherapy
Sponsors: National Cancer Center, Korea; Boston Scientific Corporation
Not yet recruiting
-
Posted: December 8th, 2023, 3:00am GMT
Conditions: Congenital Biliary Dilatation
Interventions: Other: Contrast-enhanced computed tomography (CECT) and 3D morphological analysis
Sponsors: Tsinghua University; Beijing Tsinghua Chang Gung Hospital
Completed
-
Posted: December 7th, 2023, 3:00am GMT
Conditions: Locally Advanced Cholangiocarcinoma; Intrahepatic Cholangiocarcinoma; Solid Tumor; Metastatic Cholangiocarcinoma
Interventions: Drug: Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles; Drug: Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles
Sponsors: Tyra Biosciences, Inc
Recruiting
-
Posted: November 24th, 2023, 3:00am GMT
Conditions: Liver Cancer
Interventions: Other: phenotyping
Sponsors: Inserm U955
Recruiting
-
Posted: November 20th, 2023, 3:00am GMT
Conditions: Intrahepatic Cholangiocarcinoma; Cholangiocarcinoma, Intrahepatic
Interventions: Procedure: Liver Transplant
Sponsors: Rutgers, The State University of New Jersey
Recruiting
-
Posted: November 16th, 2023, 3:00am GMT
Conditions: Carcinoma; Intrahepatic Cholangiocarcinoma; Gallbladder Cancer; Surufatinib; Angiogenesis Inhibitors; Tislelizumab; Antineoplastic Agents, Immunological; Immunotherapy
Interventions: Drug: HAIC; Drug: Surufatinib; Drug: Tislelizumab
Sponsors: Wuhan Union Hospital, China
Not yet recruiting
-
Posted: November 16th, 2023, 3:00am GMT
Conditions: Unresectable Pancreatic Cancer; Unresectable Bile Duct Carcinoma; Unresectable Biliary Tract Carcinoma
Interventions: Drug: Tripegfilgrastim
Sponsors: National Cancer Center, Korea; Seoul National University Hospital
Not yet recruiting
-
Posted: November 9th, 2023, 3:00am GMT
Conditions: Perihilar Cholangiocarcinoma
Interventions: Procedure: Liver transplantation
Sponsors: Azienda Sanitaria Ospedaliera; Istituto Oncologico Veneto IRCCS
Recruiting
-
Posted: November 1st, 2023, 2:00am GMT
Conditions: Cholangitis; Pancreatic Cancer; Choledocholithiasis; Choledochal Cyst
Interventions: Drug: Ketamine; Drug: Midazolam; Drug: Pethidin
Sponsors: National University of Malaysia
Recruiting
-
Posted: October 31st, 2023, 2:00am GMT
Conditions: Biliary Tract Cancer
Interventions: Drug: Rilvegostomig; Drug: Placebo; Drug: Capecitabine; Drug: Gemcitabine/Cisplatin; Drug: S-1 [Tegafur/Oteracil/gimeracil]
Sponsors: AstraZeneca
Recruiting
-
Posted: October 24th, 2023, 2:00am GMT
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Procedure: Liver transplantation
Sponsors: Azienda Sanitaria Ospedaliera; Istituto Oncologico Veneto IRCCS
Recruiting
-
Posted: September 28th, 2023, 2:00am GMT
Conditions: Cholangiocarcinoma Metastatic
Interventions: Drug: TT-00420 (tinengotinib)
Sponsors: TransThera Sciences (Nanjing), Inc.
Recruiting
-
Posted: September 28th, 2023, 2:00am GMT
Conditions: Locally Advanced Intrahepatic Cholangiocarcinoma; Oligometastatic Intrahepatic Cholangiocarcinoma; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Procedure: Angiography; Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Biological: Durvalumab; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Biological: Tremelimumab; Procedure: Yttrium-90 Microsphere Radioembolization
Sponsors: Mayo Clinic
Not yet recruiting
-
Posted: August 30th, 2023, 2:00am GMT
Conditions: Borderline Resectable Carcinoma; Biliary Tract Cancer
Interventions: Drug: Durvalumab; Drug: Tremelimumab; Drug: Gemcitabine; Drug: Cisplatin; Procedure: Surgical Resection
Sponsors: Georgetown University; AstraZeneca
Recruiting
-
Posted: August 14th, 2023, 2:00am GMT
Conditions: HER2 Gene Mutation
Interventions: Combination Product: Injection of IAH0968+Gemcitabine+Cisplatin; Combination Product: Gemcitabine+Cisplatin
Sponsors: SUNHO(China)BioPharmaceutical CO., Ltd.
Recruiting
-
Posted: August 1st, 2023, 2:00am GMT
Conditions: Cholangiocarcinoma
Interventions: Drug: Pembrolizumab; Drug: Gemcitabine; Drug: Cisplatin
Sponsors: M.D. Anderson Cancer Center
Recruiting
-
Posted: June 27th, 2023, 2:00am GMT
Conditions: IDH1-mutant Cholangiocarcinoma
Interventions: Drug: Ivosidenib; Drug: Recommended Combination Dose (RCD) of ivosidenib; Drug: Nivolumab; Drug: Ipilimumab
Sponsors: Servier Bio-Innovation LLC; Institut de Recherches Internationales Servier
Recruiting
-
Posted: June 22nd, 2023, 2:00am GMT
Conditions: Primary Sclerosing Cholangitis; Inflammatory Bowel Diseases
Interventions: Drug: Rosuvastatin
Sponsors: Stanford University
Recruiting
-
Posted: May 25th, 2023, 2:00am GMT
Conditions: Cholangiocarcinoma
Interventions: Drug: Ivosidenib Oral Tablet
Sponsors: Servier Affaires Médicales
Recruiting
-
Posted: May 24th, 2023, 2:00am GMT
Conditions: Cholangiocarcinoma
Interventions: Drug: GNS561 + Trametinib
Sponsors: Genfit
Recruiting
-
Posted: May 24th, 2023, 2:00am GMT
Conditions: Advanced Solid Tumor; Metastatic Solid Tumor; Lung Cancer; Colorectal Cancer; Pancreatic Cancer; Cholangiocarcinoma; Head and Neck Cancer; Non Small Cell Lung Cancer
Interventions: Biological: WM-A1-3389; Biological: Pembrolizumab
Sponsors: Wellmarker Bio; Merck Sharp & Dohme LLC
Recruiting
-
Posted: May 9th, 2023, 2:00am GMT
Conditions: Biliary Cancer; Bile Duct Cancer; Cancer of the Bile Duct
Interventions: Drug: oxaliplatin; Drug: capecitabine; Biological: Keytruda; Biological: CDX-1140
Sponsors: National Cancer Institute (NCI)
Not yet recruiting
-
Posted: April 27th, 2023, 2:00am GMT
Conditions: Cirrhosis; Cirrhosis, Liver; Cirrhosis Early; Cirrhosis Due to Hepatitis B; Cirrhosis Advanced; Cirrhosis Infectious; Cirrhosis Alcoholic; Cirrhosis, Biliary; Cirrhosis Cryptogenic; Cirrhosis Due to Hepatitis C; Cirrhosis Due to Primary Sclerosing Cholangitis
Interventions: Drug: Rosuvastatin
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); The Cleveland Clinic; Columbia University; Weill Medical College of Cornell University; Duke University; Mayo Clinic; University of Miami; University of Michigan; University of California, San Diego; University of California, San Francisco; LAC+USC Medical Center; Virginia Commonwealth University; National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Cancer Institute (NCI); University of Southern California
Recruiting
-
Posted: April 21st, 2023, 2:00am GMT
Conditions: Advanced Cholangiocarcinoma
Interventions: Drug: Lenvatinib, tislelizumab, gemcitabine and cisplatin; Drug: Gemcitabine and cisplatin
Sponsors: Second Affiliated Hospital, School of Medicine, Zhejiang University; The First Affiliated Hospital of Zhengzhou University; The Affiliated Tumor Hospital of Xinjiang Medical University
Recruiting
-
Posted: April 18th, 2023, 2:00am GMT
Conditions: Cholangiocarcinoma With IDH1 Mutation; Solid Tumors With IDH1 Mutation
Interventions: Drug: AB-218 capsule
Sponsors: AnHeart Therapeutics Inc.
Recruiting
-
Posted: March 29th, 2023, 2:00am GMT
Conditions: Non-small Cell Lung Cancer; Gastric Cancer; Head and Neck Cancer; Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer; Bladder Urothelial Carcinoma; Colorectal Cancer; Esophageal Cancer; Hepatic Cancer; Renal Cell Carcinoma; Cholangiocarcinoma; Pancreatic Cancer; Other Solid Tumors
Interventions: Drug: CDX-585
Sponsors: Celldex Therapeutics
Recruiting
-
Posted: March 27th, 2023, 2:00am GMT
Conditions: Primary Biliary Cholangitis; Heart Failure; Digestive Diseases; Women Who Have Experienced a Cardiac Event; Cirrhosis, Liver; Post-Transplant; Cancer; Chronic Kidney Diseases; Other Chronic Physical Condition
Interventions: Behavioral: Online mind-body wellness program; Behavioral: Online mind-body wellness program + Weekly Check-ins
Sponsors: University of Alberta; Canadian Institutes of Health Research (CIHR)
Recruiting
-
Posted: March 16th, 2023, 2:00am GMT
Conditions: Biliary Tract Cancer
Interventions: Biological: Durvalumab; Drug: Gemcitabine monotherapy; Drug: Gemcitabine + cisplatin; Drug: Gemcitabine + oxaliplatin; Drug: Gemcitabine + carboplatin; Drug: Gemcitabine + cisplatin + S-1; Drug: Gemcitabine + S-1; Drug: Gemcitabine + cisplatin + albumin-bound paclitaxel
Sponsors: AstraZeneca
Recruiting
-
Posted: March 1st, 2023, 3:00am GMT
Conditions: Autoimmune Hepatitis; Primary Sclerosing Cholangitis
Interventions: Other: No interventions
Sponsors: Children's Hospital Medical Center, Cincinnati
Recruiting
-
Posted: February 23rd, 2023, 3:00am GMT
Conditions: Cirrhosis; Cirrhosis, Liver; Cirrhosis Early; Cirrhosis Due to Hepatitis B; Cirrhosis Advanced; Cirrhosis Infectious; Cirrhosis Alcoholic; Cirrhosis, Biliary; Cirrhosis Cryptogenic; Cirrhosis Due to Hepatitis C; Cirrhosis Due to Primary Sclerosing Cholangitis
Sponsors: Northwestern University; The Cleveland Clinic; Columbia University; Weill Medical College of Cornell University; Duke University; Mayo Clinic; University of Miami; University of Michigan; University of California, San Diego; University of California, San Francisco; LAC+USC Medical Center; Virginia Commonwealth University; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Cancer Institute (NCI); University of Southern California; Central Virginia Veterans Healthcare System
Recruiting
-
Posted: February 21st, 2023, 3:00am GMT
Conditions: Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Drug: Camrelizumab; Drug: Gemcitabine Injection; Drug: Cisplatin injection; Drug: Cisplatin-Eluting Beads; Procedure: D-TACE
Sponsors: Hua Li
Recruiting
-
Posted: February 17th, 2023, 3:00am GMT
Conditions: Locally Advanced Solid Tumor
Interventions: Drug: TNG462
Sponsors: Tango Therapeutics, Inc.
Recruiting
-
Posted: February 14th, 2023, 3:00am GMT
Conditions: Advanced Cholangiocarcinoma; FGFR2 Fusions; Gene Rearrangement
Interventions: Drug: TAS-120
Sponsors: Taiho Oncology, Inc.
Recruiting
-
Posted: February 13th, 2023, 3:00am GMT
Conditions: Hepatobiliary Cancer; Liver Cancer; Cholangiocarcinoma; Hepatocellular Carcinoma
Interventions: Drug: Zimberelimab; Drug: Domvanalimab
Sponsors: University of Texas Southwestern Medical Center; Arcus Biosciences, Inc.; Cancer Prevention Research Institute of Texas
Recruiting
-
Posted: February 3rd, 2023, 3:00am GMT
Conditions: Head and Neck Squamous Cell Carcinoma; Advanced Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer; Cholangiocarcinoma; Gallbladder Cancer; Gallbladder Carcinoma; Intrahepatic Cholangiocarcinoma; Extrahepatic Cholangiocarcinoma; Bile Duct Cancer; Cancer of the Head and Neck; HNSCC; Oropharynx Cancer; Oral Cavity Cancer; Hypopharynx Cancer; Larynx Cancer; Oral Cavity Squamous Cell Carcinoma; Squamous Cell Carcinoma of Head and Neck; Squamous Cell Carcinoma of the Head and Neck; Squamous Cell Carcinoma of the Larynx; Squamous Cell Carcinoma of the Hypopharynx; Squamous Cell Carcinoma of the Oral Cavity; Squamous Cell Carcinoma of the Oropharynx; Gall Bladder Cancer; Gall Bladder Carcinoma; Oropharynx Squamous Cell Carcinoma; Hypopharynx Squamous Cell Carcinoma; Larynx Squamous Cell Carcinoma
Interventions: Drug: LSTA1; Drug: Paclitaxel; Drug: Durvalumab; Drug: Cisplatin; Drug: Gemcitabine; Drug: Placebo
Sponsors: Lisata Therapeutics, Inc.
Recruiting
-
Posted: January 11th, 2023, 3:00am GMT
Conditions: Esophageal Neoplasms
Interventions: Diagnostic Test: KCNA3 and OTOP2 Gene Methylation Combined Detection Kit (Fluorescent PCR Method)
Sponsors: Wuhan Ammunition Life-tech Co., Ltd; Changhai Hospital
Completed
-
Posted: January 10th, 2023, 3:00am GMT
Conditions: Hilar Cholangiocarcinoma; Intrahepatic Cholangiocarcinoma; Common Bile Duct Neoplasms; Cholangiocarcinoma; Adenocarcinoma
Interventions: Procedure: Endoscopic Ultrasound registration
Sponsors: Erasmus Medical Center
Recruiting
-
Posted: January 10th, 2023, 3:00am GMT
Conditions: Locally Advanced Cholangiocarcinoma
Sponsors: CHA University
Recruiting
-
Posted: January 10th, 2023, 3:00am GMT
Conditions: Intrahepatic Cholangiocarcinoma (ICC)
Interventions: Drug: ICP-192
Sponsors: Beijing InnoCare Pharma Tech Co., Ltd.
Recruiting
-
Posted: December 30th, 2022, 3:00am GMT
Conditions: Solid Tumor, Adult; Refractory Cancer; Bladder Urothelial Carcinoma; Cholangiocarcinoma; Adenocarcinoma of the Colon; Endometrial Carcinoma; Head and Neck Carcinoma; Cutaneous Melanoma; Non-small Cell Lung Cancer; Adenocarcinoma of the Rectum
Interventions: Drug: GV20-0251; Drug: GV20-0251
Sponsors: GV20 Therapeutics
Recruiting
-
Posted: December 19th, 2022, 3:00am GMT
Conditions: Bile Duct Cancer; Cholangiocarcinoma; Cholangiocarcinoma Non-resectable; Cholangiocarcinoma Metastatic; Metastatic Intrahepatic Cholangiocarcinoma
Interventions: Drug: Gemcitabine; Drug: Cisplatin; Drug: Durvalumab; Radiation: Yttrium-90
Sponsors: Beth Israel Deaconess Medical Center; AstraZeneca; Sirtex Medical; Dana-Farber Cancer Institute
Recruiting
-
Posted: December 8th, 2022, 3:00am GMT
Conditions: Gastrointestinal Cancers; Cholangiocarcinoma; Gastric Cancer; Colorectal Cancer; Pancreatic Ductal Adenocarcinoma; Hepatocellular Carcinoma
Interventions: Drug: [18F]FAPI-74 PET/CT
Sponsors: SOFIE
Recruiting
-
Posted: November 14th, 2022, 3:00am GMT
Conditions: Biliary Tract Neoplasms
Interventions: Drug: Futibatinib; Drug: Ivosidenib; Drug: Zanidatamab; Drug: Trastuzumab; Drug: Neratinib; Drug: Encorafenib; Drug: Binimetinib; Drug: Niraparib; Drug: Cisplatin; Drug: Gemcitabine
Sponsors: UNICANCER; Cancer Research UK & UCL Cancer Trials Centre; Belgian Group of Digestive Oncology; National Cancer Institute, France; Cancer Research UK; Taiho Oncology, Inc.; Servier; Zymeworks Inc.; Accord Healthcare, Inc.; Pierre Fabre Medicament; GlaxoSmithKline Research & Development Limited
Not yet recruiting
-
Posted: October 6th, 2022, 2:00am GMT
Conditions: Ovarian Cancer; Cholangiocarcinoma Recurrent; Mesothelioma, Malignant
Interventions: Biological: SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR
Sponsors: Verismo Therapeutics
Recruiting
-
Posted: October 3rd, 2022, 2:00am GMT
Conditions: Cervical Cancer; Colorectal Cancer; Esophageal Cancer; Gastric Cancer; Glioblastoma Multiforme; Cholangiocarcinoma; Hepatocellular Carcinoma; Head and Neck Squamous Cell Carcinoma; Nasopharyngeal Carcinoma; Non Small Cell Lung Cancer; Small Cell Lung Cancer; Epithelial Ovarian Cancer; Pancreatic Ductal Adenocarcinoma; Soft Tissue Sarcoma
Interventions: Drug: 89Zr-DFO-girentuximab
Sponsors: Telix International Pty Ltd
Recruiting
-
Posted: September 30th, 2022, 2:00am GMT
Conditions: Gastric Outlet Obstruction
Interventions: Procedure: Surgical gastrojejunostomy (SGJ); Procedure: Endoscopic gastrojejunostomy (EGJ)
Sponsors: Northwell Health
Recruiting
-
Posted: September 22nd, 2022, 2:00am GMT
Conditions: Hilar Cholangiocarcinoma
Interventions: Drug: Photosensitizer; Procedure: Radiofrequency ablation (RFA)
Sponsors: University of Leipzig; Zentrum für Klinische Studien Leipzig
Recruiting
-
Posted: September 8th, 2022, 2:00am GMT
Conditions: Advanced Cholangiocarcinoma
Interventions: Drug: Lenvatinib, tislelizumab, gemcitabine and cisplatin; Drug: gemcitabine and cisplatin
Sponsors: Second Affiliated Hospital, School of Medicine, Zhejiang University
Recruiting
-
Posted: August 26th, 2022, 2:00am GMT
Conditions: Pancreas Adenocarcinoma; Cholangiocarcinoma
Interventions: Drug: CRGD-ZW800-1; Device: Intraoperative near-infrared fluorescence imaging
Sponsors: Leiden University Medical Center
Recruiting
-
Posted: August 25th, 2022, 2:00am GMT
Conditions: Resectable Intrahepatic Cholangiocarcinoma; Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8; Stage I Intrahepatic Cholangiocarcinoma AJCC v8; Stage II Intrahepatic Cholangiocarcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8
Interventions: Drug: Cisplatin; Drug: Gemcitabine Hydrochloride; Drug: Infigratinib Phosphate; Drug: Nab-paclitaxel
Sponsors: Emory University; National Cancer Institute (NCI)
Withdrawn
-
Posted: August 23rd, 2022, 2:00am GMT
Conditions: Pancreatic Neoplasms; Solid Tumors; Biliary Tract Cancer; Lung Neoplasms; Bladder Cancer
Interventions: Drug: brigimadlin
Sponsors: Boehringer Ingelheim
Recruiting
-
Posted: August 18th, 2022, 2:00am GMT
Conditions: Biliary Tract Cancer; Cholangiocarcinoma; Gall Bladder Cancer; Ampullary Cancer
Interventions: Drug: CTX-009; Drug: Paclitaxel
Sponsors: Compass Therapeutics
Recruiting
-
Posted: July 18th, 2022, 2:00am GMT
Conditions: Pleural Effusion, Malignant; Ascites, Malignant; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Carcinoma, Renal; Carcinoma, Small Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Neuroendocrine; Carcinoma, Thymic; Carcinoma, Pancreatic; Carcinoma Breast; Carcinoma, Ovarian; Carcinoma Bladder; Carcinoma of Unknown Primary; Carcinoma of the Head and Neck; Carcinoma of the Oropharynx; Carcinoma of the Larynx; Carcinoma of the Bladder; Carcinoma of Esophagus; Carcinoma of the Nasopharynx; Carcinoma of the Penis; Carcinoma of the Cervix; Carcinoma of the Anus; Carcinoma of the Vulva; Carcinoma of the Appendix; Carcinoma of the Oral Cavity; Cholangiocarcinoma; Melanoma; Mesothelioma; Pancreatic Cancer
Sponsors: Travera Inc; xCures
Recruiting
-
Posted: July 11th, 2022, 2:00am GMT
Conditions: Mesothelioma; Mesotheliomas Pleural; Mesothelioma, Malignant; Mesothelioma Peritoneum; Ovarian Cancer; Ovarian Serous Adenocarcinoma; Pancreatic Cancer; Pancreatic Adenocarcinoma; Colorectal Cancer; Triple Negative Breast Cancer; TNBC - Triple-Negative Breast Cancer; Ovarian Adenocarcinoma; Pancreatic Neoplasms; Colorectal Neoplasms; Ovarian Neoplasms; Cholangiocarcinoma; Non Small Cell Lung Cancer
Interventions: Biological: TC-510; Drug: Fludarabine; Drug: Cyclophosphamide
Sponsors: TCR2 Therapeutics
Active, not recruiting
-
Posted: June 16th, 2022, 2:00am GMT
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Induction Chemotherapy Triplet Therapy; Radiation: Concurrent Y-90 treatment; Drug: Consolidation Doublet Therapy:
Sponsors: Inova Health Care Services
Not yet recruiting
-
Posted: June 9th, 2022, 2:00am GMT
Conditions: Gastrointestinal Cancer; Cholangiocarcinoma; Liver Cancer; Colorectal Adenocarcinoma; Pancreatic Cancer; Gastric Cancer; Esophageal Adenocarcinoma; Gastroesophageal Junction
Interventions: Drug: Cabotamig (ARB202)
Sponsors: Arbele Pty Ltd
Recruiting
-
Posted: April 14th, 2022, 2:00am GMT
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Perflutren Protein-Type A Microspheres; Procedure: Contrast-Enhanced Ultrasound
Sponsors: Thomas Jefferson University
Recruiting
-
Posted: April 13th, 2022, 2:00am GMT
Conditions: Solid Tumors
Interventions: Drug: Bemarituzumab
Sponsors: Amgen
Recruiting
-
Posted: April 11th, 2022, 2:00am GMT
Conditions: Cholangiocarcinoma; Liver Fluke-Related Cholangiocarcinoma; Opisthorchiasis
Interventions: Behavioral: eCHEC program
Sponsors: McMaster University; Khon Kaen University; Global Alliance for Chronic Diseases (GACD); Canadian Institutes of Health Research (CIHR)
Not yet recruiting
-
Posted: March 23rd, 2022, 2:00am GMT
Conditions: Primary Liver Cancer; Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma; Combined Hepatocellular-cholangiocarcinoma
Interventions: Other: Observation
Sponsors: Geneplus-Beijing Co. Ltd.; Eastern Hepatobiliary Surgery Hospital
Withdrawn
-
Posted: March 18th, 2022, 2:00am GMT
Conditions: Metastatic Colorectal Cancer (Mcrc); Intrahepatic Cholangiocarcinoma (Icc); Colorectal Cancer; Colorectal Neoplasms; Cholangiocarcinoma; Intrahepatic Bile Duct Cancer; Bile Duct Cancer; Bile Duct Neoplasms
Interventions: Drug: Floxuridine; Drug: 5-Fluorouracil; Drug: Irinotecan; Device: Intera 3000 Hepatic Artery Infusion Pump (HAIP); Drug: Oxaliplatin; Drug: Leucovorin; Drug: M9241; Drug: Gemcitabine; Drug: Dexamethasone
Sponsors: National Cancer Institute (NCI)
Recruiting